Defective amplification of the late phase insulin response to glucose by GIP in obese Type II diabetic patients
Open accessThe DOI matches its Crossref record; 41 of the 41 references it cites were found in a registry or an index.
Abstract
Aims/hypothesis Glucagon-like-peptide-1 (GLP-1) is strongly insulinotropic in patients with Type II (non-insulin-dependent) diabetes mellitus, whereas glucose-dependent insulinotropic polypeptide (GIP) is less effective. Our investigation evaluated "early" (protocol 1) - and "late phase" (protocol 2) insulin and C-peptide responses to GLP-1 and GIP stimulation in patients with Type II diabetes.Methods Protocol 1: eight Type II diabetic patients and eight matched healthy subjects received i.v. bolus injections of GLP-1(2.5 nmol) or GIP(7.5 nmol) concomitant with an increase of plasma glucose to 15 mmol/l. Protocol 2: eight Type II diabetic patients underwent a hyperglycaemic clamp (15 mmol/l) with infusion (per kg body weight/min) of either: 1 pmol GLP-1 (7-36) amide (n=8), 4 pmol GIP (n=8), 16 pmol GIP (n=4) or no incretin hormone (n=5). For comparison, six matched healthy subjects were examined.Results Protocol 1: Type II diabetic patients were characterised by a decreased "early phase" response to both stimuli, but their relative response to GIP versus GLP-1 stimulation was exactly the same as in healthy subjects [insulin (C-peptide): patients 59+/-9% (74+/-6%) and healthy subjects 62+/-5% (71+/-9%)]. Protocol 2, "Early phase" (0-20 min) insulin response to glucose was delayed and reduced in the patients, but enhanced slightly and similarly by GIP and GLP-1. GLP-1 augmented the "late phase" (20-120 min) insulin secretion to levels similar to those observed in healthy subjects. In contrast, the "late phase" responses to both doses of GIP were not different from those obtained with glucose alone. Accordingly, glucose infusion rates required to maintain the hyperglycaemic clamp in the "late phase" period (20-120 min) were similar with glucose alone and glucose plus GIP, whereas a doubling of the infusion rate was required during GLP-1 stimulation.Conclusion/interpretation Lack of GIP amplification of the late phase insulin response to glucose, which contrasts markedly to the normalising effect of GLP-1, could be a key defect in insulin secretion in Type II diabetic patients.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Nevertheless, whereas the insulinotropic effects of GLP-1 are only marginally impaired in T2D, GIP has lost much of its action for largely unknown reasons [19].”
From Adipose Tissue: A Novel Target of the Incretin Axis? A Paradigm Shift in Obesity-Linked Insulin Resistance (2024) · cites this paper as [19]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Report of the Expert Committee on the Diagnosis and Classification of Diabetes Mellitus
The Expert Committee on the Diagnosis and Classification of Diabetes Mellitus* (2002) · Diabetes Care · doi:10.2337/diacare.25.2007.s5 · Cited by 10,338
Report of the Expert Committee on the Diagnosis and Classification of Diabetes Mellitus
The Expert Committee on the Diagnosis and Classification of Diabetes Mellitus (1997) · Diabetes Care · doi:10.2337/diacare.20.7.1183 · Cited by 6,220
Nauck, M. A., Heimesaat, M. M., Orskov, C., Holst, J. J., Ebert, R., & Creutzfeldt, W. (1993) · Journal of Clinical Investigation · doi:10.1172/jci116186 · Cited by 1,651 · cited 1×
“Previous studies have indicated that whereas GLP-1 is strongly insulinotropic in patients with Type II diabetes mellitus, the effect of GIP is much weaker or absent [5, 6]; although, in another study, GIP appeared to retain some activity [7].”
ResultReduced incretin effect in Type 2 (non-insulin dependent) diabetes
Nauck, M., Stöckmann, F., Ebert, R., & Creutzfeldt, W. (1986) · Diabetologia · doi:10.1007/bf02427280 · Cited by 1,307
Kieffer, T. J., & Francis Habener, J. (1999) · Endocrine Reviews · doi:10.1210/edrv.20.6.0385 · Cited by 1,062 · cited 1×
“It is often assumed that GLP-1 is more potent than GIP [19], but by infusing GIP at three times the rate of GLP-1, we sought to compensate for any difference in potency.”
BackgroundTissue and Plasma Concentrations of Amidated and Glycine-Extended Glucagon-Like Peptide I in Humans
Ørskov, C., Rabenhøj, L., Wettergren, A., Kofod, H., & Holst, J. J. (1994) · Diabetes · doi:10.2337/diab.43.4.535 · Cited by 919 · cited 1×
“The C-terminal immunoreactivity of GLP-1 was measured [16], using standards of synthetic GLP-1 (7–36)”
MethodReport of the Expert Committee on the Diagnosis and Classification of Diabetes Mellitus
The Expert Committee On The Diagnosis And Classification Of Diabetes Mellitus (1998) · Diabetes Care · doi:10.2337/diacare.21.1.s5 · Cited by 897
Vilsbøll, T., Krarup, T., Deacon, C. F., Madsbad, S., & Holst, J. J. (2001) · Diabetes · doi:10.2337/diabetes.50.3.609 · Cited by 884 · cited 2×
“In the Type II diabetic patients, the “early phase” insulin response was grossly reduced and delayed, both in response to glucose alone or to glucose plus incretin hormones but, in agreement with findings in part one, both GIP and GLP-1 augmented the “early phase” response to values similar to those observed in protoc…”
BackgroundResultNAUCK, M. A., HOMBERGER, E., SIEGEL, E. G., ALLEN, R. C., EATON, R. P., EBERT, R., & CREUTZFELDT, W. (1986) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem-63-2-492 · Cited by 874 · cited 1×
“Patients with Type II (non-insulin-dependent) diabetes are characterised by an impaired incretin effect [2, 3].”
BackgroundRadioimmunological determination of human C-peptide in serum
Heding, L. G. (1975) · Diabetologia · doi:10.1007/bf01222104 · Cited by 830
Deacon, C. F., Nauck, M. A., Meier, J., Hücking, K., & Holst, J. J. (2000) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.85.10.6855 · Cited by 401 · cited 1×
“Intact, biologically active GIP was measured using a newly developed assay [15].”
MethodOrskov, C., Jeppesen, J., Madsbad, S., & Holst, J. J. (1991) · Journal of Clinical Investigation · doi:10.1172/jci115012 · Cited by 378 · cited 1×
“The sensitivity is approximately 1 pmol/l, and the intra-assay coefficient of variation is below 6% in the range between 10 and 25 pmol/l [18].”
BackgroundElahi, D., McAloon-Dyke, M., Fukagawa, N. K., Meneilly, G. S., Sclater, A. L., Minaker, K. L., Habener, J. F., & Andersen, D. K. (1994) · Regulatory Peptides · doi:10.1016/0167-0115(94)90136-8 · Cited by 309 · cited 1×
“Previous studies have indicated that whereas GLP-1 is strongly insulinotropic in patients with Type II diabetes mellitus, the effect of GIP is much weaker or absent [5, 6]; although, in another study, GIP appeared to retain some activity [7].”
ResultDeacon, C. F. (2000) · Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.85.10.3575 · Cited by 301
Cellular regulation of islet hormone secretion by the incretin hormone glucagon-like peptide 1
Gromada, J., Holst, J. J., & Rorsman, P. (1998) · Pfl�gers Archiv European Journal of Physiology · doi:10.1007/s004240050558 · Cited by 258 · cited 1×
“It was, therefore, concluded that the two receptors are likely to activate the same intracellular machinery [30].”
BackgroundMeier, J. J., Hücking, K., Holst, J. J., Deacon, C. F., Schmiegel, W. H., & Nauck, M. A. (2001) · Diabetes · doi:10.2337/diabetes.50.11.2497 · Cited by 230
Characterization of Seven C-peptide Antisera
Faber, O. K., Binder, C., Markussen, J., Heding, L. G., Naithani, V. K., Kuzuya, H., Blix, P., Horwitz, D. L., & Rubenstein, A. H. (1978) · Diabetes · doi:10.2337/diab.27.1.s170 · Cited by 229 · cited 1×
“In protocol 1, C-peptide concentrations were measured by radioimmunoassay (RIA) [11] using the polyclonal antibody M1230 [12].”
MethodKieffer, T. J. (1999) · Endocrine Reviews · doi:10.1210/er.20.6.876 · Cited by 219
Gut hormones and diabetes mellitus
Creutzfeldt, W., & Nauck, M. (1992) · Diabetes/Metabolism Reviews · doi:10.1002/dmr.5610080206 · Cited by 176 · cited 1×
“the enhanced insulin secretion after oral versus intravenous administration of glucose [1].”
BackgroundKrarup, T., Madsbad, S., Moody, A. J., Regeur, L., Faber, O. K., Holst, J. J., & Sestoft, L. (1983) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem-56-6-1306 · Cited by 151 · cited 1×
“Total GIP was measured using the C-terminally directed antiserum R65 [13, 14], which reacts fully with intact GIP and the N-terminally truncated metabolite, GIP (3–42).”
MethodTissue and plasma concentrations of amidated and glycine-extended glucagon-like peptide I in humans
Ørskov, C., Rabenhøj, L., Wettergren, A., et al. (1994) · Diabetes · doi:10.2337/diabetes.43.4.535 · Cited by 143
The pathogenesis of NIDDM involves a defective expression of the GIP receptor
Holst, J. J., Gromada, J., & Nauck, M. A. (1997) · Diabetologia · doi:10.1007/s001250050779 · Cited by 136 · cited 1×
“We previously hypothesised, that the lack of a functional receptor was the cause of the impaired response to GIP in Type II diabetic patients [29].”
BackgroundGromada, J., Dissing, S., Bokvist, K., Renström, E., Frøkjær-Jensen, J., Wulff, B. S., & Rorsman, P. (1995) · Diabetes · doi:10.2337/diab.44.7.767 · Cited by 125 · cited 1×
“Several studies have shown that intracellular actions of the two hormones are similar: they generate identical changes of membrane potential, intracellular calcium responses, membrane currents, and cAMP responses [24, 25, 26 ].”
BackgroundDing, W.-G., & Gromada, J. (1997) · Diabetes · doi:10.2337/diab.46.4.615 · Cited by 120 · cited 1×
“Several studies have shown that intracellular actions of the two hormones are similar: they generate identical changes of membrane potential, intracellular calcium responses, membrane currents, and cAMP responses [24, 25, 26].”
BackgroundKrarup, T., & Holst, J. J. (1984) · Regulatory Peptides · doi:10.1016/0167-0115(84)90005-3 · Cited by 109 · cited 1×
“Total GIP was measured using the C-terminally directed antiserum R65 [13, 14], which reacts fully with intact GIP and the N-terminally truncated metabolite, GIP (3–42).”
MethodPotential Therapeutic Levels of Glucagon-Like Peptide I Achieved in Humans by a Buccal Tablet
Gutniak, M. K., Larsson, H., Heiber, S. J., Juneskans, O. T., Holst, J. J., & Ahrén, B. (1996) · Diabetes Care · doi:10.2337/diacare.19.8.843 · Cited by 99 · cited 1×
“was measured using antiserum 93242 [17], which cross-reacts approximately 10% with GLP-1 (1–36) amide, and less than”
MethodGutniak, M. K., Juntti-Berggren, L., Hellström, P. M., Guenifi, A., Holst, J. J., & Efendic, S. (1996) · Diabetes Care · doi:10.2337/diacare.19.8.857 · Cited by 70 · cited 1×
“Furthermore, the insulinotropic effects of both peptides are similarly potentiated by sulfonylurea treatment and similarly augmented in the genetically obese (fa/fa) Zucker rat [27, 28].”
BackgroundAlmind, K., Ambye, L., Urhammer, S. A., Hansen, T. F., Echwald, S. M., Holst, J. J., Gromada, J., Thorens, B., & Pedersen, O. B. (1998) · Diabetologia · doi:10.1007/s001250051051 · Cited by 68 · cited 1×
“Molecular genetic studies have shown sequence variations in the human GIP receptor [31, 32], but no clinically significant mutations.”
BackgroundGromada, J., Rorsman, P., Dissing, S., & Wulff, B. S. (1995) · FEBS Letters · doi:10.1016/0014-5793(95)01070-u · Cited by 66 · cited 1×
“Several studies have shown that intracellular actions of the two hormones are similar: they generate identical changes of membrane potential, intracellular calcium responses, membrane currents, and cAMP responses [24, 25, 26].”
BackgroundKubota, A., Yamada, Y., Hayami, T., Yasuda, K., Someya, Y., Ihara, Y., Kagimoto, S., Watanabe, R., Taminato, T., Tsuda, K., et al. (1996) · Diabetes · doi:10.2337/diab.45.12.1701 · Cited by 62 · cited 1×
“Molecular genetic studies have shown sequence variations in the human GIP receptor [31, 32], but no clinically significant mutations.”
BackgroundSignal transmission after GLP-1(7-36)amide binding in RINm5F cells
Goke, R., Trautmann, M. E., Haus, E., Richter, G., Fehmann, H. C., Arnold, R., & Goke, B. (1989) · American Journal of Physiology-Gastrointestinal and Liver Physiology · doi:10.1152/ajpgi.1989.257.3.g397 · Cited by 54 · cited 1×
“The differential responsiveness to GIP and GLP-1 is surprising, because their beta-cell signal transduction mechanisms involve many common steps, except for transmission via closely related, but highly specific receptors for each hormone [21, 22, 23].”
BackgroundRadioimmunological Determination of Human C-Peptide in Serum
Hedïng, L. G. (1988) · Springer eBooks · doi:10.1007/978-94-011-7094-9_10 · Cited by 48
Gallwitz, B., Witt, M., Morys‐Wortmann, C., Fölsch, U. R., & Schmidt, W. E. (1996) · Regulatory Peptides · doi:10.1016/0167-0115(96)00019-5 · Cited by 46 · cited 1×
“The differential responsiveness to GIP and GLP-1 is surprising, because their beta-cell signal transduction mechanisms involve many common steps, except for transmission via closely related, but highly specific receptors for each hormone [21, 22, 23].”
BackgroundThe Effect of Glyburide on β-Cell Sensitivity to Glucose-Dependent Insulinotropic Polypeptide
Meneilly, G. S., Bryer-Ash, M., & Elahi, D. (1993) · Diabetes Care · doi:10.2337/diacare.16.1.110 · Cited by 40 · cited 1×
“Previous studies have indicated that whereas GLP-1 is strongly insulinotropic in patients with Type II diabetes mellitus, the effect of GIP is much weaker or absent [5, 6]; although, in another study, GIP appeared to retain some activity [7].”
ResultDing, W. G., & Gromada, J. (1997) · Diabetes · doi:10.2337/diabetes.46.4.615 · Cited by 38
Evaluation of beta-cell secretory capacity using glucagon-like peptide 1.
Vilsbøll, T., Toft-Nielsen, M. B., Krarup, T., Madsbad, S., Dinesen, B., & Holst, J. J. (2000) · Diabetes Care · doi:10.2337/diacare.23.6.807 · Cited by 37 · cited 3×
“In our study, we investigated more closely the potentiating insulinotropic effects of GIP, using the preserved response to GLP-1 as a measure of the functional beta-cell mass [8].”
MethodInfluentialGromada, J., Dissing, S., Bokvist, K. B., Renstrom, E., Frøkjaer-Jensen, J., Wulff, B. S., & Rorsman, P. (1995) · Diabetes · doi:10.2337/diabetes.44.7.767 · Cited by 20 · cited 1×
“Several studies have shown that intracellular actions of the two hormones are similar: they generate identical changes of membrane potential, intracellular calcium responses, membrane currents, and cAMP responses [24, 25, 26].”
BackgroundJia, X., Elliott, R. M., Kwok, Y. N., Pederson, R. A., & McIntosh, C. H. S. (1995) · Diabetes · doi:10.2337/diab.44.5.495 · Cited by 18 · cited 1×
“Furthermore, the insulinotropic effects of both peptides are similarly potentiated by sulfonylurea treatment and similarly augmented in the genetically obese (fa/fa) Zucker rat [27, 28].”
BackgroundKubota, A., Yamada, Y., Hayami, T., et al. (1996) · Diabetes · doi:10.2337/diabetes.45.12.1701 · Cited by 12
Jia, X., Elliott, R. M., Kwok, Y. N., et al. (1995) · Diabetes · doi:10.2337/diabetes.44.5.495 · Cited by 10
Alberti (1998) · doi:10.1002/(sici)1096-9136(199807)15:7<539::aid-dia668>3.0.co;2-s · cited 2×
“present typical outpatient obese Type II diabetic patients and they were all diagnosed according to the criteria of the World Health Organisation (WHO) [9, 10].”
Method
Research works printed but not linked: 1
- Le Febvre (1991) Abnormal secretion of glucagon. In: Samuels E (ed) The endocrine pancreas. Raven Press, New York, pp 191-205
Cited by
The Physiology of Glucagon-like Peptide 1
Holst, J. J. (2007) · Physiological Reviews · doi:10.1152/physrev.00034.2006 · Cited by 3,371
Self-citationDeFronzo, R. A., Ferrannini, E., Groop, L., Henry, R. R., Herman, W. H., Holst, J. J., Hu, F. B., Kahn, C. R., Raz, I., Shulman, G. I., et al. (2015) · Nature Reviews Disease Primers · doi:10.1038/nrdp.2015.19 · Cited by 2,611
Pathogenesis of type 2 diabetes mellitus
DeFronzo, R. A. (2004) · Medical Clinics of North America · doi:10.1016/j.mcna.2004.04.013 · Cited by 1,342
Pancreatic regulation of glucose homeostasis.
Röder, P. V., Wu, B., Liu, Y., & Han, W. (2016) · Experimental & Molecular Medicine · doi:10.1038/emm.2016.6 · Cited by 985
The Discovery and Development of Liraglutide and Semaglutide
Knudsen, L. B., & Lau, J. (2019) · Frontiers in Endocrinology · doi:10.3389/fendo.2019.00155 · Cited by 970
Metadata
- Authors
- T., V., T., K., S., M., & J., H.
- Venue
- Diabetologia
- Published
- 2002-08-01
- Volume
- 45
- Issue
- 8
- Pages
- 1111-1119
- ISSN
- 0012-186X (ISSN-L)
- 1432-0428
- OpenAlex
- W2067710447
- Cited by
- 518
- References
- 36
- Citations by year
- 2026: 9 · 2025: 17 · 2024: 20 · 2023: 13 · 2022: 19 · 2021: 16 · 2020: 22 · 2019: 33 · 2018: 24 · 2017: 22 · 2016: 22 · 2015: 23 · 2014: 21 · 2013: 25 · 2012: 25
- FWCI
- 7.41
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Diabetologia (publishedVersion)
- PubMed (publishedVersion)
- Research at the University of Copenhagen (University of Copenhagen) (publishedVersion)
- Funders
- Novo Nordisk
- Novo Nordisk Fonden
- Diabetesforeningen
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Pancreatic function and diabetes
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
- Keywords
- glucagon-like peptide-1, glucose-dependent insulinotropic polypeptide, type 2 diabetes, obesity, first-phase insulin secretion, C-peptide, incretins, hyperglycaemic clamp, glucose infusion rate, beta-cell function, incretin resistance, GLP-1(7-36)amide
- MeSH terms
- Aged, Blood Glucose, C-Peptide, Diabetes Mellitus, Diabetes Mellitus, Type 2, Drug Synergism, Female, Glucagon, Glucose, Humans, Hypoglycemic Agents, Injections, Intravenous, Insulin, Male, Middle Aged, Obesity, Peptide Fragments, Protein Precursors, Reference Values, Time Factors, Glucagon-Like Peptide 1
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.